Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
Emily M. Hsieh(Children's Hospital of Los Angeles), Patrick A. Brown(Haemonetics (United States)), Michael R. Verneris(NHS Blood and Transplant), Lee Chen(Children's Hospital of Philadelphia), Samuel John(Southwestern Medical Center), Susan R. Rheingold(Children's Hospital of Philadelphia), Nirali N. Shah(National Institutes of Health), Deepa Bhojwani(St. Jude Children's Research Hospital), Bonnie Yates(National Institutes of Health), Agne Taraseviciute(Seattle Children's Hospital), Perry Chung(Children's Hospital of Philadelphia), Lia Gore(Children's Hospital Colorado), Seth M. Steinberg(National Institutes of Health), Amanda M. DiNofia(Children's Hospital of Philadelphia), Jennifer Sheppard(Southwestern Medical Center), Daniel W. Lee(University of Virginia Cancer Center), Stephan A. Grupp(Children's Hospital of Philadelphia), Rebecca Gardner(Seattle Children's Hospital), Theodore W. Laetsch(Children's Hospital of Philadelphia), Regina M. Myers(Children's Hospital of Philadelphia), Michael A. Pulsipher(Primary Children's Hospital), Colleen Annesley(Unknown)
Cited by 34
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795